At the European Association for the Study of Diabetes meeting, Louis J. Aronne, MD, argued that obesity medications could make bariatric surgery obsolete, thanks to drugs that treat multiple metabolic conditions. Francesco Rubino, MD, countered, suggesting “metabolic” surgery will continue to play a key role, especially for long-term management of obesity and related conditions. Aronne believes future treatments will address obesity earlier, while Rubino sees surgery remaining important for certain patients. Both agree obesity management is evolving rapidly.
Trending
- Multitarget Stool DNA Versus Fecal Immunochemical Testing: A National Assessment of Follow-Up Colonoscopy by Race and Ethnicity (National Comprehensive Cancer Network)
- Physician Fee Schedule 2027: What physicians need to know now (Medical Economics)
- Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
- What Happens to Independent Medicine When Private Equity Shows Up With a Checkbook (MedCity News)
- AGA launches AI-powered virtual assistant for gastroenterology and hepatology care (News Medical)
- AMSURG Acquires 5 Endoscopy Centers in North Carolina (ASC News)
- Hawaii mandates free follow-up colonoscopies, wipes $91M in medical debt (Becker’s Healthcare)
- Endo Tools Therapeutics Secures $23 million in Series C Financing to Advance The endomina® technology and Commercialization of New endomina EZFuse System (Endo Tools Therapeutics)
